Series: Cardiovascular outcome trials for diabetes drugs Saxagliptin and SAVOR-TIMI 53
DOI:
https://doi.org/10.15277/bjd.2019.213Keywords:
diabetes, cardiovascular outcome trial, saxagliptinAbstract
SAVOR-TIMI 53 was the first FDA-mandated cardiovascular outcome trial to be presented and published. It compared saxagliptin and placebo in 16,492 patients with type 2 diabetes. SAVOR-TIMI 53 demonstrated non-inferiority for major cardiovascular events (cardiovascular death, myocardial infarction, stroke) but not superiority. An unexpected statistically significant increase in adjudicated hospitalisation for heart failure was seen in the saxagliptin group. Post hoc analysis demonstrated that subjects at greatest risk for hospitalisation for heart failure had previous heart failure, an estimated glomerular filtration rate <60 mL/min, or elevated baseline levels of N-terminal pro-B type natriuretic peptide. As other dipeptidyl peptidase 4 (DPP-4) inhibitors are available which have not been associated with an increased risk of hospitalisation for heart failure, saxagliptin should be avoided in patients with heart failure or a reduced estimated glomerular filtration rate.
References
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457–71. https://doi.org/10.1056/NEJMoa072761
Food and Drug Administration. Guidance for industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2008. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf (accessed 9 Feb 2019).
European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. London: EMA, 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf (accessed 9 Feb 2019).
Scirica BM, Bhatt DL, Braunwald E, et al for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–26. https://doi.org/10.1056/NEJMoa1307684
White WB, Cannon CP, Heller SR, et al for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369;1327–35. https://doi.org/10.1056/NEJMoa1305889
Green JB, Bethel A, Armstrong PW, et al for the TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–42. https://doi.org/10.1056/NEJMoa1501352
Rosenstock J, Perkovic V, Johansen OE, et al for the CARMELINA Investigators. Effects of linagliptin versus placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and high renal risk. The CARMELINA randomized clinical trial. JAMA 2019; 321:69–79. https://doi.org/10.1001/jama.2018.18269.
Pfeffer MA, Claggett B, Diaz R, et al for the ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247–57. https://doi.org/10.1056/NEJMoa1509225.
Marso SP, Daniels GH, Brown-Frandsen K, et al for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311–22. https://doi.org/10.1056/NEJMoa1603827
Marso SP, Bain SC, Consoli A, et al for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44. https://doi.org/10.1056/NEJMoa1607141
Holman RR, Bethel MA, Mentz RJ, et al for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228–39. https://doi.org/10.1056/NEJMoa1612917
Hernandez AF, Green JB, Janmohamed S, et al for the Harmony Outcomes Committees and Investigators. Albiglutide and cardiovascular outcomes in people with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised, placebo-controlled trial. Lancet 2018;392:1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X
Zinman B, Wanner C, Lachin JM, et al for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720
Neal B, Perkovic V, Mahaffey KW, et al for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925
Wiviott SD, Bonaca MP, Mosenzon O, et al for the DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57. https://doi.org/10.1056/NEJMoa1812389
Marso SP, McGuire DK, Zinman B, et al for the DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377:723–32. https://doi.org/10.1056/NEJMoa1615692
Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16–27. https://doi.org/10.3810/pgm.2010.05.2138
Scirica BM, Bhaat DL, Braunwald E, et al. The design and rationale of the Saxglitin Assessment of Vascualr Outcomes Recorded in patients with diabetes-mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162:818–25. https://doi.org/10.1016/j.ahj.2011.08.006
Mosenzon O, Raz I, Scirica BM, et al. Baseline characteristics of the patient population in the Saxaglitin Assessment of Vascualr Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 2013;29:417–26. https://doi.org/10.1002/dmrr.2413
Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1579–88. https://doi.org/10.1161/CIRCULATIONAHA.114.010389
Standl E, Erbach M, Schnell O. Dipeptidyl-peptidase-4 Inhibitors and heart failure: class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med 2014;16:353. https://doi.org/10.1007/s11936-014-0353-y
Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 2017;40:69–76. https://doi.org/10.2337/dc16-0621
Haluzik M, Frolik J, Rychlik I. Renal effects of DPP-4 inhibitors: a focus on microalbuminuria. Int J Endocrinol 2013;2013:895102. https://doi.org/10.1155/2013/895102 [Epub 2013 Sep 5]
Udell JA, Bhatt DL, Braunwald E, et al for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. Diabetes Care 2015;38:696–705. https://doi.org/10.2337/dc14-1850
Leiter LA, Teoh H, Braunwald E, et al for the SAVOR-TIMI 53 Steering Committee and Investigators. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 2015;38:1145–53. https://doi.org/10.2337/dc14-2868
Cavender MA, Scirica BM, Raz I, et al. Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline hemoglobin A1c. Am J Med 2016;129:340e1–8. https://doi.org/10.1016/j.amjmed.2015.09.022
Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicentre trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care 2014;37:2435–41. https://doi.org/10.2337/dc13-2546
Leiter LA, Teoh H, Mosenzon O, et al for the SAVOR-TIMI 53 Steering Committee and Investigators. Frequency of cancer events in the SAVOR-TIMI 53 trial. Diabetes Obes Metab 2015;18:186–90. https://doi.org/10.1111/dom.12582
Cahn A, Raz I, Mosenzon O, et al. Predisposing factors for any and major hypoglycaemia with saxagliptin versus placebo and overall: analysis from the SAVOR-TIMI 53 trial. Diabetes Care 2016;39:1329–37. https://doi.org/10.2337/dc15-2763
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.